Tag Archives: vaccine

Proceed with caution in covering the road to a COVID-19 vaccine

Bara Vaida

About Bara Vaida

Bara Vaida (@barav) is AHCJ's core topic leader on infectious diseases. An independent journalist, she has written extensively about health policy and infectious diseases. Her work has appeared in outlets that include the National Journal, Agence France-Presse, Bloomberg News, McClatchy News Service, MSNBC, NPR, Politico and The Washington Post.

Photo: U.S. Pacific Fleet via Flickr

“Curb your enthusiasm” is important advice for journalists covering the development of a COVID-19 vaccine, according to panelists at recent AHCJ webcast.

More than 120 COVID-19 vaccine candidates are being tested worldwide, with about a dozen having reached the human clinical trial stage. It’s perhaps the fastest ever that scientists and drug companies worldwide have mobilized to create a vaccine to fight a virus. Continue reading

Webcast: Understanding the path to a COVID-19 vaccine

Bara Vaida

About Bara Vaida

Bara Vaida (@barav) is AHCJ's core topic leader on infectious diseases. An independent journalist, she has written extensively about health policy and infectious diseases. Her work has appeared in outlets that include the National Journal, Agence France-Presse, Bloomberg News, McClatchy News Service, MSNBC, NPR, Politico and The Washington Post.

Photo: U.S. Pacific Fleet via Flickr

The race to develop a vaccine against SARS-CoV2, the virus that causes COVID-19, is picking up speed with early promising results from initial studies, and President Trump predicting there will be “hundreds of millions of doses” of vaccine by the end of 2020.

Journalists have reported on these early results, as well as Trump’s comments, which may leave the public with a misunderstanding about the process of vaccine development. Continue reading

Older health care professionals at risk during COVID-19 outbreak

Liz Seegert

About Liz Seegert

Liz Seegert (@lseegert), is AHCJ’s topic editor on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News, the Connecticut Health I-Team and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.

Photo: Medical Reserve CorpsA member of the Medical Reserve Corps of
Puerto Rico conducts a medical assessment in response to an earthquake.

Retired physicians, nurses and other health care professionals have been asked to volunteer for duty in the wake of the coronavirus pandemic.

However, many of these retirees fall into the high-risk group for contracting COVID-19. They face a difficult choice: stay away and stay safer, or put aside the potential risk to help care for an increasingly sick population. Continue reading

Despite pronouncements, no quick turnaround likely for COVID-19 treatments, vaccines

Bara Vaida

About Bara Vaida

Bara Vaida (@barav) is AHCJ's core topic leader on infectious diseases. An independent journalist, she has written extensively about health policy and infectious diseases. Her work has appeared in outlets that include the National Journal, Agence France-Presse, Bloomberg News, McClatchy News Service, MSNBC, NPR, Politico and The Washington Post.

whitehouse.gov

An inaccurate statement that President Trump made during a March 19 news briefing — that the malaria drug hydroxychloroquine had been approved as a COVID-19 treatment — demonstrates how skeptical journalists should remain when covering the unfolding story about treatments and preventative measures.

While there are more than 85 trials for vaccines and treatments underway for COVID-19, scientists don’t expect them to be available to the public soon, despite what some headlines suggest. Continue reading

Drug companies ramp up development of COVID-19 prevention and treatment products

Bara Vaida

About Bara Vaida

Bara Vaida (@barav) is AHCJ's core topic leader on infectious diseases. An independent journalist, she has written extensively about health policy and infectious diseases. Her work has appeared in outlets that include the National Journal, Agence France-Presse, Bloomberg News, McClatchy News Service, MSNBC, NPR, Politico and The Washington Post.

COVID-19

Photo: NIAID-RML via FlickrAn electron microscope image of SARS-CoV-2 — also known as 2019-nCoV — which is the virus that causes COVID-19.

With the number of COVID-19 cases expanding exponentially, the story about the potential for treatments and vaccines remains a top priority. So does the story of drug pricing.

At a March 5 media briefing on Capitol Hill, biopharmaceutical company executives updated legislaters on potential medical countermeasures for stopping the SARS-CoV-2 virus, which causes the disease COVID-19.

One of the most promising drugs is remdesivir, an antiviral under development by biotech company Gilead Sciences. Continue reading

U.S. vaccine safety system needs greater visibility, webcast panelists say

Bara Vaida

About Bara Vaida

Bara Vaida (@barav) is AHCJ's core topic leader on infectious diseases. An independent journalist, she has written extensively about health policy and infectious diseases. Her work has appeared in outlets that include the National Journal, Agence France-Presse, Bloomberg News, McClatchy News Service, MSNBC, NPR, Politico and The Washington Post.

PHOTO: SELF MAGAZINE VIA FLICKR

As state legislators have grappled with policies to address vaccine hesitancy, public health officials and journalists could do more to emphasize that the United States has a well-established and effective vaccine safety surveillance system, policy experts told AHCJ members during a Nov. 21 webcast.

The U.S. engages several agencies and organizations, including the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration, the Health Resources and Services Administration, and the National Academy of Medicine, plus eight health care systems and seven academic hospitals in monitoring vaccine safety. Continue reading